A5064906574- Endometrial and Cervical Cancer Treatments
- Economic and Financial Impacts of Cancer
- Health Systems, Economic Evaluations, Quality of Life
- Data Quality and Management
- Cancer survivorship and care
- Prostate Cancer Treatment and Research
- Cervical Cancer and HPV Research
- Medication Adherence and Compliance
- Bone health and treatments
- Reconstructive Surgery and Microvascular Techniques
- Palliative Care and End-of-Life Issues
- Lipoproteins and Cardiovascular Health
- Lymphoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Mobile Health and mHealth Applications
- Colorectal and Anal Carcinomas
- CAR-T cell therapy research
- Statistical Methods in Clinical Trials
- Lung Cancer Treatments and Mutations
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Patient-Provider Communication in Healthcare
NHS Greater Glasgow and Clyde
2018-2023
NHS Lanarkshire
2023
Beatson West of Scotland Cancer Centre
2019-2021
St Bartholomew's Hospital
1991
Abstract Purpose New treatments are introduced into standard care based on clinical trial results. However, it is not clear if these benefits reflected in the broader population. This study analysed outcomes of patients with metastatic castration‐resistant prostate cancer, treated abiraterone and enzalutamide, within Scottish National Health Service. Methods Retrospective cohort using record linkage routinely collected healthcare data (study period: February 2012 to 2017). Overall survival...
Background Cancer treatment is a key component of health care systems, and the increasing number cancer medicines expanding landscape. However, evidence impact on patients has been focused more chemotherapy toxicity symptom control less effect broadly patients’ lives. Evolving electronic patient-reported outcome measures (ePROMs) presents opportunity to secure early engagement clinicians in shaping collection quality-of-life metrics presenting these data better support patient-clinician...
To identify what matters to clinicians and patients when discussing cancer medicines' impact on health-related quality of life (HRQoL).A framework HRQoL domain/domain elements was developed, informed by analysis published patient reported outcome measures (PROMs), applicable prostate cancer. Using mixed methods (eDelphi, Nominal Group Technique questionnaire), attending clinics support groups were asked which domains/domain would be important them the medicines have their HRQoL.Twenty-one 71...
The efficacy and safety of cancer medicines as reported from randomised clinical trials do not always translate into similar benefits in routine practice; hence, post-marketing studies are a useful addition to the evidence base. With recent advances digital infrastructure advent electronically available health records, linkage routinely collected data has emerged promising evaluation method for these studies. This paper discusses opportunities challenges when applying an electronic record...
Objective: To report the outcomes of neoadjuvant chemotherapy (NACT) in patients with locally advanced cervical cancer, we conducted a retrospective study 126 patients.Methods: The electronic prescribing system was used to identify from West Scotland Cancer Network who received NACT over 5 year period.Baseline characteristic and treatments details were collected.Association treatment type other variables overall survival (OS) analysed using Cox proportional hazards model.Results: median...
The aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated (pre-chemotherapy) who had previously received docetaxel-based (post-chemotherapy), before commencing these medicines.A retrospective cost analysis of mCRPC commenced enzalutamide between 2012 2015 conducted. Routinely collected datasets from largest health...
Objective: To determine the feasibility and overall survival (OS) outcome of utilizing neoadjuvant chemotherapy (NACT) followed by wide local excision (WLE) in women with sphincter-threatening locally advanced squamous cell carcinoma (SCC) vulva.Methods: The electronic prescribing system was used to identify patients from West Scotland Cancer Network (WoSCAN) who received NACT over a 5 year period, January 2012 December 2016 inclusive.Baseline characteristics treatment details were...
Aim: Assess the real-world effectiveness of systemic anticancer therapy in advanced (unresectable or metastatic) melanoma. Methods: This was a retrospective cohort study linking routine healthcare data with prescriptions for patients starting immunotherapy targeted treatments between 1 November 2010 and 31 December 2017 west Scotland. Results: Among 362 identified, median overall survival varied 18.5 months (95% CI: 14.4-not estimable) ipilimumab/nivolumab combination 5.6 4.5-7.3)...
<sec> <title>BACKGROUND</title> Cancer treatment is a key component of health care systems, and the increasing number cancer medicines expanding landscape. However, evidence impact on patients has been focused more chemotherapy toxicity symptom control less effect broadly patients’ lives. Evolving electronic patient-reported outcome measures (ePROMs) presents opportunity to secure early engagement clinicians in shaping collection quality-of-life metrics presenting these data better support...
Journal Article BSR CONFERENCE REPORT: CONTRACTING FOR RHEUMATOLOGY SERVICES 14 December 1990 Get access D. L. SCOTT, SCOTT St Bartholomew's Hospital, West Smithfield, London EC1A 7BE Correspondence to Dr Scott. Search for other works by this author on: Oxford Academic PubMed Google Scholar B. BOURKE, BOURKE I. HASLOCK, HASLOCK K. BAILLIE Rheumatology, Volume 30, Issue 3, June 1991, Pages 200–202, https://doi.org/10.1093/rheumatology/30.3.200 Published: 01 1991 history Received: 28 January...
<h3>Introduction/Background</h3> Limited studies suggest that locally advanced vulval cancer may be rendered more operable with neoadjuvant chemotherapy (NACT). In the West of Scotland Cancer Network (WoSCAN), NACT is offered to women sphincter threatening disease. A previous local audit in 2012 reported an operability rate 35% and median overall survival (OS) 20 months, following NACT. This study aimed identify proportion patients who proceed tailored surgery wide excision ± groin node...
<h3>Introduction/Background</h3> Neoadjuvant chemotherapy (NACT) is increasingly used in locally advanced or selected stage 4B endometrial cancer that considered unsuitable for primary surgery, despite the lack of randomised evidence. In West Scotland Cancer Network (WoSCAN), NACT offered to women with inoperable disease limited (omental/peritoneal involvement and/or small volume lung metastases/pleural effusion). This study aimed identify proportion patients proceeding delayed surgery...
<h3>Introduction/Background</h3> Concurrent chemoradiotherapy (CCRT) is the standard of care for locally advanced cervical cancer. However, a significant number women develop local and/or systemic relapse. Limited studies suggest that neoadjuvant chemotherapy (NACT) may improve efficacy, with 3 year overall survival (OS) 67% in recent Phase II study (McCormack M, et al; 2013). In West Scotland Cancer Network (WoSCAN), 3-weekly NACT has been used over decade high-risk women. A previous 2012...
Abstract Objectives To discuss the opportunities and challenges when applying an electronic record linkage methodology with respect to systemic anti-cancer therapy, highlight some of potential pitfalls spanning entire breadth depth research process. Design Retrospective cohort studies using routinely collected, administrative health data. Setting: Scotland Results Studies conducted to-date have indicated that collected data determine outcomes treatment cancer medicines is feasible, albeit...
<h3>Introduction/Background*</h3> Management of endometrial cancer (EC) consists surgery, followed by tailored adjuvant therapy in intermediate to high-risk disease. PORTEC3 reported 5-year overall survival (OS) 81% and 25% relapse rate (pelvic failure 6% distant 24%) women who received concurrent chemoradiotherapy 4 cycles chemotherapy, with most marked benefit demonstrated stage III and/or high grade serous (HGS) EC. In the West Scotland Cancer Network (WoSCAN), standard post-operative...